Daniel Woolson - 07 Mar 2026 Form 4 Insider Report for ICU MEDICAL INC/DE (ICUI)

Role: VP, GM-Infusion Capital
Signature: By: Paula Darbyshire, Attorney-in-Fact For: Daniel Woolson
Issuer symbol: ICUI
Transactions as of: 07 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 09 Mar 2026, 16:15:50 UTC
Previous filing: 25 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Woolson Daniel	VP, GM-Infusion Capital	951 CALLE AMANECER, SAN CLEMENTE	By: Paula Darbyshire, Attorney-in-Fact For: Daniel Woolson	09 Mar 2026	0001698998

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ICUI	Common Stock	Options Exercise		+1,585	+14%	$0.000000^*	12,882	07 Mar 2026	Direct
transaction	ICUI	Common Stock	Tax liability		-702	-5.4%	$132.00^*	12,180	07 Mar 2026	Direct
transaction	ICUI	Common Stock	Options Exercise		+16,147	+133%	$0.000000^*	28,327	08 Mar 2026	Direct	F1
transaction	ICUI	Common Stock	Tax liability		-6,877	-24%	$132.00^*	21,450	08 Mar 2026	Direct
transaction	ICUI	Common Stock	Options Exercise		+2,153	+10%	$0.000000^*	23,603	08 Mar 2026	Direct	F2
transaction	ICUI	Common Stock	Tax liability		-630	-2.7%	$132.00^*	22,973	08 Mar 2026	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ICUI	Common Stock	Options Exercise		-2,153	-24%	$0.000000^*	6,908	08 Mar 2026	Common Stock	2,153		Direct	F2, F3, F4, F5
transaction	ICUI	Performance Shares	Options Exercise		-16,147	-100%	$0.000000^*	0	08 Mar 2026	Common Stock	16,147	$0.000000	Direct	F1, F6, F7
transaction	ICUI	Performance Shares	Options Exercise		-1,585	-33%	$0.000000^*	3,170	07 Mar 2026	Common Stock	1,585		Direct	F7, F8, F9

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the settlement of performance stock units granted on 3/8/2024. Upon the certification of performance results by the Compensation Committee on 2/11/26, the PRSUs were earned at 250% of target, resulting in the acquisition of the shares reported herein.
F2	These securities are Restricted Stock Units.
F3	There is neither a purchase price nor an exercise price for the Restricted Stock Units.
F4	One third of the units subject to the award shall vest on each of the first, second, and third anniversaries of the grant date.
F5	These are restricted stock units that fully vest 3 years from the grant date.
F6	These Securities are Performance-based Restricted Stock Units (PRSU).
F7	There is neither a purchase price nor an exercise price for the PRSUs.
F8	One-third of the shares shall vest on each of the first, second, and third anniversaries of the grant date. The vested shares shall become exercisable if, during the term of the option, the closing price of the Company's common stock is equal to or more than one-hundred and thirty percent of the exercise price per share for thirty consecutive trading days. The appreciation must occur within four years from the grant date.
F9	Vesting of these performance stock units are subject to the satisfaction of both performance-based conditions and time-based criteria. If earned, these PRSUs vest on the first, second, and third year following the year of grant.